Home Stock

Stock Research: Nxera Pharma

Independent, rules-based stock research to judge this stock's true performance: Cut through market noise and find high-growth or high-value gems from 8,000+ stocks worldwide.

Nxera Pharma

TYO:4565 JP3431300007
87
  • Value
    94
  • Growth
    99
  • Safety
    Safety
    4
  • Combined
    88
  • Sentiment
    59
  • 360° View
    360° View
    87
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Nxera Pharma Co Ltd is a Japan-based biopharmaceutical company engaged in drug research, development, and sale, focusing on the pharmaceutical business. The company's main businesses include drug discovery, translational medicine, preclinical and early clinical development, as well as the research and development, import/export, packaging, and sale of pharmaceuticals. It also conducts structural analysis of G protein-coupled receptors (GPCRs), creates initial lead compounds, and searches for candidate products using StaR technology. In the last fiscal year, the company had 374 employees, a market cap of $525 million, profits of $135 million, and revenue of $183 million.

more

ANALYSIS: With an Obermatt 360° View of 87 (better than 87% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Nxera Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Nxera Pharma. The consolidated Value Rank has an attractive rank of 94, which means that the share price of Nxera Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 94% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 99, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 59. But the company’s financing is risky with a Safety rank of 4. This means 96% of comparable companies have a safer financing structure than Nxera Pharma. ...read more

more
Strongest Rank Safety
Weakest Rank Growth
Country Japan
Industry Pharmaceuticals
Size Small
Website nxera.life
Index
Nxera Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 13-Mar-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
94 32 26 21
Growth
99 78 7 75
Safety
Safety
4 22 26 32
Sentiment
59 18 16 29
360° View
360° View
87 4 1 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
39 67 54 76
Opinions Change
50 57 50 79
Pro Holdings
n/a 16 4 12
Market Pulse
53 3 7 7
Sentiment
59 18 16 29
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
94 32 26 21
Growth
99 78 7 75
Safety Safety
4 22 26 32
Combined
88 9 1 43
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
68 46 28 11
Price vs. Earnings (P/E)
61 21 28 31
Price vs. Book (P/B)
84 67 47 56
Dividend Yield
83 23 19 14
Value
94 32 26 21
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
96 89 100 6
Profit Growth
95 89 1 98
Capital Growth
98 63 1 81
Stock Returns
59 4 7 45
Growth
99 78 7 75
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
11 6 17 32
Refinancing
43 86 73 75
Liquidity
21 10 20 20
Safety Safety
4 22 26 32

Similar Stocks

Discover high‑ranked alternatives to Nxera Pharma and broaden your portfolio horizons.

Daiwa House

TYO:1925
Country: Japan
Industry: Electric Utilities
Size: XX-Large
Full Stock Analysis

Kinden

TYO:1944
Country: Japan
Industry: Construction & Engineering
Size: X-Large
Full Stock Analysis

NGK Insulators

TYO:5333
Country: Japan
Industry: Industrial Machinery
Size: X-Large
Full Stock Analysis

Inpex

TYO:1605
Country: Japan
Industry: Oil & Gas Production
Size: X-Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews